CML: Mechanisms of Resistance & Treatment: Elias Jabbour, Sameer A. Parikh, Hagop Kantarjian, Jorge Cortes, published online 20 October 2011.

This article is free so I have posted the link below. You just need to click on the button which say access this article for free and it should take you to the correnct page to view the full text. Hope this one works.

Sandy

Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non–tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

http://download.journals.elsevierhealth.com/pdfs/journals/0889-8588/PIIS0889858811001018.pdf